

## 20.11.2023

To.

National Stock Exchange of India Limited "Exchange Plaza", Bandra-Kurla Complex, Bandra (East) Mumbai 400 051

**BSE Limited** Floor-25, PJ Tower, Dalal Street. Mumbai 400 001

SYMBOL:- EPIGRAL

Scrip Code: 543332

Dear Sirs,

Subject: Disclosure under Regulation 30 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (Listing Regulations)

We are pleased to inform that the Company opens its first Research and Development Centre (R&D Centre) at Changodar, Ahmedabad, Gujarat.

The detailed Press Release is attached herewith for information of the Members.

Thanking you,

Yours faithfully, For Epigral Limited (formerly known as 'Meghmani Finechem Limited')

K. D. Mehta **Company Secretary and Compliance Officer** Membership No. FCS 2051



## **Epigral Limited opens its first R&D Centre in Ahmedabad**

- R&D centre spread across 14,374 sq.mt
- Built with an investment of Rs. 30 Cr.

**Ahmedabad, November 20, 2023:** Epigral Ltd, one of India's leading integrated chemical manufacturers, today launched its first research and development centre at Ahmedabad, Gujarat. This is a significant step for the company in enhancing its research capabilities and accelerating its journey towards building Specialty products.

Located at Changodar in Ahmedabad, the R&D centre is built over 14,374 sq. mt and has the latest, state-of-the-art technologies installed that will enable Epigral to catalyse identification of specialty chemical molecules for later introduction in India. The company has consciously strived towards creating a key differentiator for itself by graduating from being a chemical manufacturer to developing research-driven products, in-house.

The centre has been developed with an initial investment of Rs. 30 Cr. and the company will further invest to enhance its capability as its proceeds further.

Commenting on this Mr. Maulik Patel, Chairman & Managing Director of Epigral Ltd. said, "Epigral's R&D centre is a stepping stone towards creating molecules with far-reaching applications for manufacturing pharmaceutical and agrochemical active ingredients. Our investment in research emphasises our focus on steady progress of our company thereby also boosting India's Atmanirbhar capabilities. We want to keep introducing new molecules in the Indian market and make it self-sufficient with our import-substitutes."

Through research and development, the company intends to introduce new molecules indigenous to India and address domestic and global custom manufacturing requirements. This centre will help discovering new molecules within the Chlorotoluene ecosystem and further establish advanced specialty intermediates.

## **About Epigral Ltd:**

Epigral Limited (formerly known as Meghmani Finechem Ltd), was incorporated in 2007. It is a leading integrated manufacturer of chemicals in India. Its futuristic manufacturing facilities in Gujarat, Dahej – a leading PCPIR region in the country, is a backward and forward integrated and automated complex with a well-established infrastructure and Captive Power Plants. In India, Epigral is the 1st to set up an Epichlorohydrin plant and has the largest capacity plant of CPVC Resin. Epigral is India's 4th largest manufacturer of Caustic Soda, Chlorine and Hydrogen and a leading manufacturer of Caustic Potash, Chloromethanes and Hydrogen Peroxide. Epigral is strengthening its position in the specialty chemical segment by expanding CPVC Resin capacity to 75,000 TPA, setting up CPVC Compound capacity of 35,000 TPA and entering into Chlorotoluenes Value chain.

The company is focused on sustainable value creation for all its stakeholders and has been awarded with the Responsible Care certificate. Through integral collaborations and exceptional solutions, Epigral strives to enhance value and exceed expectations, transforming the company as a global multi-product chemical conglomerate.